H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 103 from SEK 111 and keeps a Buy rating on the shares. The firm views the company’s Q4 report as “encouraging.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNSBF:
- Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
- Hansa Biopharma Delivers Strong Q4 Growth and Files FDA Application for Imlifidase
- Hansa Biopharma Sets February Date for 2025 Year-End Results Call
- Hansa Biopharma Wins 2025 SwedenBIO Award as Late-Stage Pipeline Advances
- Hansa Biopharma initiated with an Outperform at Wedbush